Prospera Financial Services Inc Buys Shares of 4,125 Prometheus Biosciences, Inc. (NASDAQ:RXDX)

Prospera Financial Services Inc bought a new stake in Prometheus Biosciences, Inc. (NASDAQ:RXDXGet Rating) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 4,125 shares of the biopharmaceutical company’s stock, valued at approximately $156,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Values First Advisors Inc. purchased a new position in Prometheus Biosciences in the first quarter valued at about $227,000. Calamos Advisors LLC purchased a new position in Prometheus Biosciences in the first quarter valued at about $1,800,000. Nisa Investment Advisors LLC acquired a new stake in Prometheus Biosciences in the first quarter worth about $31,000. DekaBank Deutsche Girozentrale boosted its holdings in Prometheus Biosciences by 10.0% in the first quarter. DekaBank Deutsche Girozentrale now owns 14,300 shares of the biopharmaceutical company’s stock worth $537,000 after acquiring an additional 1,300 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Prometheus Biosciences in the first quarter worth about $86,000. Hedge funds and other institutional investors own 65.41% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. SVB Leerink reissued an “outperform” rating on shares of Prometheus Biosciences in a report on Thursday, May 12th. Piper Sandler initiated coverage on Prometheus Biosciences in a report on Friday, June 10th. They issued an “overweight” rating and a $53.00 price target for the company. The Goldman Sachs Group initiated coverage on Prometheus Biosciences in a report on Wednesday, July 20th. They set a “buy” rating and a $51.00 target price for the company. Finally, Guggenheim lifted their target price on Prometheus Biosciences to $75.00 and gave the stock an “outperform” rating in a report on Wednesday, July 27th. Ten analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $54.20.

Prometheus Biosciences Trading Up 5.1 %

Shares of NASDAQ:RXDX opened at $45.58 on Friday. The company has a market capitalization of $1.79 billion, a PE ratio of -15.46 and a beta of 2.57. Prometheus Biosciences, Inc. has a 12-month low of $21.05 and a 12-month high of $51.96. The business has a 50 day moving average of $30.02 and a two-hundred day moving average of $34.14. The company has a current ratio of 13.56, a quick ratio of 13.56 and a debt-to-equity ratio of 0.07.

Prometheus Biosciences (NASDAQ:RXDXGet Rating) last posted its quarterly earnings data on Thursday, May 12th. The biopharmaceutical company reported ($0.82) EPS for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.04). The business had revenue of $3.92 million during the quarter, compared to analysts’ expectations of $0.70 million. Prometheus Biosciences had a negative net margin of 1,722.58% and a negative return on equity of 43.92%. As a group, analysts forecast that Prometheus Biosciences, Inc. will post -3.63 EPS for the current year.

Prometheus Biosciences Profile

(Get Rating)

Prometheus Biosciences, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease.

See Also

Want to see what other hedge funds are holding RXDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prometheus Biosciences, Inc. (NASDAQ:RXDXGet Rating).

Institutional Ownership by Quarter for Prometheus Biosciences (NASDAQ:RXDX)

Want More Great Investing Ideas?

Receive News & Ratings for Prometheus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prometheus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.